Accure Therapeutics

Executive Summary

Accure Therapeutics is a private, Barcelona-based R&D pharmaceutical company founded in 2019, dedicated to discovering and developing innovative small molecule therapies for severe central nervous system (CNS) disorders. The company aims to deliver disease-modifying treatments that address high unmet medical needs in areas such as neurodegenerative and neuroinflammatory diseases. With a focus on oral small molecules that can cross the blood-brain barrier, Accure leverages deep expertise in CNS pharmacology to advance a pipeline of proprietary candidates from discovery through clinical development. Accure is currently in Phase 2 clinical development with its lead asset, targeting a CNS indication with potential for disease modification. The company has progressed efficiently since its founding, demonstrating preclinical proof-of-concept and early clinical safety. Upcoming milestones include the readout of Phase 2 efficacy data, which will be pivotal for advancing the program toward registration and potential partnerships. With a lean, experienced team and a capital-efficient model, Accure is positioned to create significant value in the CNS space.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Topline Efficacy Data Readout50% success
• Q4 2026Regulatory End-of-Phase 2 Meeting80% success
• Q1 2027Potential Strategic Partnership or Licensing Deal40% success